{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:34:09Z","timestamp":1790379249448,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In this position statement the British and Irish Hypertension Society (BIHS) present a review of the current evidence for blood pressure (BP) treatment thresholds and targets. The BIHS recommend initiating pharmacological antihypertensive therapy, irrespective of cardiovascular disease risk, following a confirmed diagnosis of hypertension (sustained out-of-office BP\u2009\u2265\u2009135\/85\u2009mmHg despite diet and lifestyle advice). The BIHS recommend an on-treatment BP target &lt; 130\/80\u2009mmHg or as low as reasonably achievable without causing unacceptable side-effects, within 6-months of initiating treatment, for all adults. Possible subgroups to whom this may not apply are those who are frail and\/or have limited life expectancy where higher targets may be appropriate based on clinical judgement and the individuals\u2019 tolerance to treatment. The BIHS believe that this simple 2-step approach will facilitate practitioners deliver evidence-based best practice, discourage therapeutic inertia around BP lowering and improve heath outcomes for all adults living with high BP.<\/jats:p>","DOI":"10.1038\/s41371-025-01055-z","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T11:38:55Z","timestamp":1753270735000},"page":"537-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Call to action: British and Irish hypertension society position statement on blood pressure treatment thresholds and targets"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1066-6899","authenticated-orcid":false,"given":"Luca","family":"Faconti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayanatara","family":"Tantirige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6292-997X","authenticated-orcid":false,"given":"Neil R.","family":"Poulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Kapil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-8503","authenticated-orcid":false,"given":"Ajay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2568-9871","authenticated-orcid":false,"given":"Pauline A.","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Heagerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Shantsila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8434-2896","authenticated-orcid":false,"given":"Sarah","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-9399","authenticated-orcid":false,"given":"Ian B.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"1055_CR1","unstructured":"British Heart Foundation (2025) UK Factsheet January 2025. Available from: https:\/\/www.bhf.org.uk\/-\/media\/files\/for-professionals\/research\/heart-statistics\/bhf-cvd-statistics-uk-factsheet.pdf [accessed 19\/5\/2025]"},{"key":"1055_CR2","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903\u201313. Erratum in: Lancet. 2003 Mar 22;361(9362):1060","journal-title":"Lancet"},{"key":"1055_CR3","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","volume":"383","author":"E Rapsomaniki","year":"2014","unstructured":"Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1\u00b725 million people. Lancet. 2014;383:1899\u2013911.","journal-title":"Lancet"},{"key":"1055_CR4","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1161\/CIRCULATIONAHA.120.049819","volume":"143","author":"M Arvanitis","year":"2021","unstructured":"Arvanitis M, Qi G, Bhatt DL, Post WS, Chatterjee N, Battle A, et al. Linear and nonlinear Mendelian randomization analyses of the association between diastolic blood pressure and cardiovascular events: the J-curve revisited. Circulation. 2021;143:895\u2013906.","journal-title":"Circulation"},{"key":"1055_CR5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamacardio.2020.1731","volume":"5","author":"SP Whelton","year":"2020","unstructured":"Whelton SP, McEvoy JW, Shaw L, Psaty BM, Lima JAC, Budoff M, et al. Association of normal systolic blood pressure level with cardiovascular disease in the absence of risk factors. JAMA Cardiol. 2020;5:1011\u20138.","journal-title":"JAMA Cardiol"},{"key":"1055_CR6","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"The Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","unstructured":"The Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. The Lancet. 2021;397:1625\u201336.","journal-title":"The Lancet"},{"key":"1055_CR7","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","volume":"398","author":"The Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","unstructured":"The Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet. 2021;398:1053\u201364.","journal-title":"Lancet"},{"key":"1055_CR8","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"The ACCORD Study Group","year":"2010","unstructured":"The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575\u201385.","journal-title":"N Engl J Med"},{"key":"1055_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(13)60852-1","volume":"382","author":"SPS3 Study Group","year":"2013","unstructured":"SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507\u201315.","journal-title":"Lancet"},{"key":"1055_CR10","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","volume":"384","author":"SPRINT Research Group","year":"2021","unstructured":"SPRINT Research Group. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021;384:1921\u201330.","journal-title":"N Engl J Med"},{"key":"1055_CR11","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jamaneurol.2019.2167","volume":"76","author":"RESPECT Study Group","year":"2019","unstructured":"RESPECT Study Group. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurol. 2019;76:1309\u201318.","journal-title":"JAMA Neurol"},{"key":"1055_CR12","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"STEP Study Group","year":"2021","unstructured":"STEP Study Group. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268\u201379.","journal-title":"N Engl J Med"},{"key":"1055_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","volume":"404","author":"ESPRIT Collaborative Group","year":"2024","unstructured":"ESPRIT Collaborative Group. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404:245\u201355.","journal-title":"Lancet"},{"key":"1055_CR14","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","volume":"392","author":"BPROAD Research Group","year":"2025","unstructured":"BPROAD Research Group. Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med. 2025;392:1155\u201367.","journal-title":"N Engl J Med"},{"key":"1055_CR15","doi-asserted-by":"publisher","first-page":"m4858","DOI":"10.1136\/bmj.m4858","volume":"372","author":"RJ McManus","year":"2021","unstructured":"McManus RJ, Little P, Stuart B, Morton K, Raftery J, Kelly J, et al. Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial. BMJ. 2021;372:m4858.","journal-title":"BMJ"},{"key":"1055_CR16","unstructured":"National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. NICE guideline [NG136]. Published 28 August 2019, Last updated: 21 November 2023. https:\/\/www.nice.org.uk\/guidance\/ng136 [accessed 20\/5\/2023]."},{"key":"1055_CR17","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912\u20134018.","journal-title":"Eur Heart J"},{"key":"1055_CR18","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874\u20132071.","journal-title":"J Hypertens"},{"key":"1055_CR19","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334\u201357.","journal-title":"Hypertension"},{"key":"1055_CR20","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/ PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology\/ american heart association task force on clinical practice guidelines. Hypertension. 2018;71:e13\u2013115.","journal-title":"Hypertension."},{"key":"1055_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41371-023-00882-2","volume":"38","author":"P Lewis","year":"2024","unstructured":"Lewis P, George J, Kapil V, Poulter NR, Partridge S, Goodman J, et al. Adult hypertension referral pathway and therapeutic management: British and Irish Hypertension Society position statement. J Hum Hypertens. 2024;38:3\u20137.","journal-title":"J Hum Hypertens"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01055-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01055-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01055-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T19:39:31Z","timestamp":1757273971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01055-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1038\/s41371-025-01055-z","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"References have been corrected on page 1.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for this work as it did not involve any human or animal studies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Professor Adrian J.B. Brady has received honoraria from Daiichi-Sankyo, Amgen, Sanofi-Aventis, Bayer, MSD, and Novartis. Professor Phil Chowienczyk has an interest in Centron Diagnostics, a company that has produced technology for blood pressure measurement. Professor Jacob George has received grants and travel funding from Astra Zeneca, Novartis and Daiichi Sankyo, is on Advisory Boards for AstraZeneca, Menarini and Novartis, consulting fees from Roche and PwC and is a Principal Investigator for studies funded by AstraZeneca, Alnylam, Novartis, Esperion. Dr Pankaj Gupta has received research grants, lecture honoraria and funding for conference attendance from Sanofi-Aventis and Amgen, and consulting fees from Ionis Pharmaceuticals. Dr Spoorthy Kulkarni is a PhD student at the University of Cambridge funded by AstraZeneca and has attended scientific advisory boards for Viatris. Professor Terry McCormack has received lecture honoraria and\/or consultation fees from AstraZeneca, Daichi-Sankyo, and Medtronic. He is a co-investigator in the Alnylam study Kardia 3. Professor Neil R Poulter has received lecture honoraria and\/or consultation fees from several pharmaceutical companies that manufacture blood pressure lowering agents including AstraZeneca, Eva Pharma, Lri Therapharma, Napi, Pfizer, Servier and Sanofi-Aventis. Dr Manish Saxena has received grant support from Recor Medical, Ablative Solutions, Applied Therapeutics, Vascular Dynamics, and MSD; and has received consulting fees from Recor Medical, Esperion Inc., Daiichi Sankyo Inc., Novartis, and Vifor Pharma. Professor Peter Sever has received renumeration for scientific advisory boards and lectures from Viatris. Professor Ian B Wilkinson has received research grants from AstraZeneca, GSK and scientific advisory board consultation fees for Viatris, Astra Zeneca and Roche. Dr Luca Faconti, Dr Ajay Gupta, Professor Anthony Heagerty, Dr Andrew Jordan, Dr Vikas Kapil, Dr Philip Lewis, Dr Ryan McNally, Ms Michaela Nuttall, Mr Sam Olden, Dr Sarah Partridge, Dr Eduard Shantsila, Professor James Sheppard, Dr Wayne Sunman, Dr Pauline Swift, Dr Nayanatara Tantirige, and Dr Helen Warren have no competing interests to declare for this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}